Drug Profile


Alternative Names: 962040; GSK 962040

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Amines; Gastrokinetics; Piperazines; Piperidines; Small molecules
  • Mechanism of Action Motilin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic gastroparesis; Gastroparesis

Most Recent Events

  • 01 Jul 2016 GlaxoSmithKline completes a phase II trial in Gastroparesis in USA, Australia and Canada (NCT01934192)
  • 02 Sep 2015 Phase-II development is ongoing for Gastroparesis and Diabetic gastroparesis in USA, Canada, Australia and the EU
  • 01 Aug 2014 GlaxoSmithKline initiates enrolment in a phase II trial for Diabetic gastroparesis in USA (NCT02210000)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top